2023
Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation
Mohamed A, Martin G, Ng S, Takiar V, Beadle B, Zafereo M, Garden A, Frank S, Fuller C, Gunn G, Morrison W, Rosenthal D, Reddy J, Moreno A, Lee A, Phan J. Patterns of failure for recurrent head and neck squamous cell carcinoma treated with salvage surgery and postoperative IMRT reirradiation. Clinical And Translational Radiation Oncology 2023, 44: 100700. PMID: 38058404, PMCID: PMC10695834, DOI: 10.1016/j.ctro.2023.100700.Peer-Reviewed Original ResearchLocoregional recurrenceSalvage surgeryRecurrent headNeck squamous cell cancerNeck squamous cell carcinomaPhysician's classificationMarginal failureSubsequent locoregional recurrenceSquamous cell cancerSquamous cell carcinomaPatterns of failureLogistic regression analysisDeformable image registrationAdjuvant reirradiationRadiological progressionSurgical salvageInitial recurrenceRecurrent diseaseSalvage rateRecurrent HNSCCCell cancerMucosal sitesCell carcinoma
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients